Irfan Kayani
University College Hospital
CancerInternal medicineRadiologyPET-CTSurgeryPathologyOncologyPerfusionCardiologyPositron emission tomographyBiopsyNeuroendocrine tumorsLymphomaTransplantationNuclear medicineIn patientFdg pet ctComputer scienceComputed tomographyMedicine
133Publications
27H-index
2,639Citations
Publications 132
Newest
#1Simon Wan (UCL: University College London)H-Index: 10
#2Marie-Elsya Speechly-Dick (UCL: University College London)
Last. Ashley M. Groves (UCL: University College London)H-Index: 48
view all 10 authors...
Source
#1Andrew Thornton (UCL: University College London)
#2Francesco Fraioli (UCL: University College London)H-Index: 23
Last. Deena Neriman (UCLH: University College Hospital)H-Index: 1
view all 16 authors...
Background: The evolution of pulmonary 18F-FDG uptake is unknown in patients with pneumonia due to SARS-CoV-2 (COVID-19 pneumonia) and in those with persistent respiratory symptoms post-COVID-19 termed Post-COVID-19 Lung-Disease (PCLD). The aim of this study was to assess the temporal evolution of pulmonary 18F-FDG uptake and identify a potential role for the use of 18F-FDG-PET/CT imaging in the management of these patients. Methods: Clinical data and CT imaging of all patients that underwent 18...
Source
#1Fuad Novruzov (UCLH: University College Hospital)H-Index: 4
Last. Irfan Kayani (UCLH: University College Hospital)H-Index: 27
view all 9 authors...
Gallium 68-tetraazacyclododecane-tetraacetic acid-octreotate ([68Ga]Ga-DOTA-TATE) is a selective somatostatin analogue ligand, which shows increased affinity for somatostatin receptor subtype (SSTR) 2 and has been used routinely for imaging neuroendocrine tumors with PET/CT. We investigated the utility of [68Ga]Ga-DOTA-TATE positron emission tomography/computed tomography (PET/CT) in patients with suspected pituitary pathology. We reviewed imaging for twenty consecutive patients (8 men, 12 women...
Source
#2Gabriel Wallis (Lond: University of London)
Last. Michael Brown (Lond: University of London)H-Index: 29
view all 9 authors...
Source
#1John Hoath (UCL: University College London)H-Index: 1
#2Leon Menezes (UCL: University College London)H-Index: 21
Last. Ashley M. Groves (UCL: University College London)H-Index: 48
view all 8 authors...
Source
#1Stefan VooH-Index: 1
#1Stefan Vöö (UCLH: University College Hospital)H-Index: 5
Last. Jamshed BomanjiH-Index: 12
view all 3 authors...
Source
#1Suzanne Arulogun (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 1
#2Maaz Ali Abbasi (UCLH: University College London Hospitals NHS Foundation Trust)
Last. Shirley D'Sa (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 21
view all 7 authors...
Source
#1Stefan Vöö (UCLH: University College Hospital)H-Index: 5
#2Deena Neriman (UCLH: University College Hospital)H-Index: 1
Last. Irfan Kayani (UCLH: University College Hospital)H-Index: 27
view all 4 authors...
4 CitationsSource
#1Asim Afaq (UCLH: University College Hospital)H-Index: 14
#2Ming Young Simon Wan (UCLH: University College Hospital)H-Index: 1
Last. Jamshed Bomanji (UCLH: University College Hospital)H-Index: 52
view all 5 authors...
1255 Objectives: The primary objective was to evaluate the phenomenon of benign bone marrow uptake which has been described with 18F-PSMA-1007 using PET/MRI. Secondary objectives were to review the initial experience and technical feasibility of staging and restaging of prostate cancer using 18F-PSMA-1007 PET/MRI and to assess if a pelvic section of Diffusion Weighted Imaging provided any additional lesion detection over the standard PET/MRI dataset. Methods: Thirty-four consecutive patients wer...
2 Citations
#1William Townsend (UCL: University College London)H-Index: 7
#1William Townsend (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 5
Last. Kirit M. Ardeshna (UCL: University College London)H-Index: 23
view all 14 authors...
This phase II trial was designed to determine the safety and efficacy of a modified paediatric risk-stratified protocol in young adults (18-30 years) with classical Hodgkin Lymphoma. The primary end-point was neurotoxicity rate. The incidence of grade 3 neurotoxicity was 11% (80% CI, 5-19%); a true rate of neuropathy of >15% cannot be excluded. Neuropathy and associated deterioration in quality of life was largely reversible. The overall response rate was 100% with 40% complete remission (CR) ra...
Source